Table 2. Clinical characteristics of 6,469 patients with prolonged and nonprolonged monkeypox virus infections, California, USA, May 12, 2022–August 31, 2024.
| Characteristic | Prolonged |
|
Nonprolonged |
|
Total |
|||
|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | |||
| Hospitalization | ||||||||
| Yes* | 21 | 25.6 (16.6–36.44) | 285 | 4.5 (3.98–5.0) | 306 | 4.7 (4.24–5.27) | ||
| No* | 49 | 59.8 (48.34–70.44) | 4,889 | 76.5 (75.49–77.57) | 4,938 | 76.3 (75.28–77.35) | ||
| Unknown |
12 |
14.6 (7.8–24.17) |
|
1,213 |
19.0 (18.05–19.97) |
|
1,225 |
18.9 (18–19.91) |
| JYNNEOS vaccination status | ||||||||
| Unvaccinated | 76 | 92.7 (84.75–97.27) | 5,458 | 85.5 (84.57–86.3) | 5,534 | 85.5 (84.67–86.38) | ||
| 1-dose vaccinated | 2 | 2.4 (0.3–8.53) | 287 | 4.5 (4.01–5.03) | 289 | 4.5 (3.99–5.0) | ||
| Postexposure vaccinated | 4 | 4.9 (1.34–12.02) | 562 | 8.8 (8.13–9.52) | 566 | 8.7 (8.09–9.46) | ||
| 2-dose vaccinated |
0 |
0.0 (0.0–4.4) |
|
80 |
1.3 (1.01–1.56) |
|
80 |
1.2 (0.99–1.54) |
| HIV status | ||||||||
| HIV-positive* | 50 | 61.0 (49.57–71.56) | 2,549 | 39.9 (38.71–41.12) | 2,599 | 40.2 (38.99–41.38) | ||
| HIV-negative* |
32 |
39.0 (28.44–50.43) |
|
3,838 |
60.1 (58.88–61.29) |
|
3,870 |
59.8 (58.62–61.01) |
| Mean symptom severity score (95% CI) |
3.51 (3.3–3.72) |
|
3.28 (3.26–3.31) |
|
3.29 (3.27–3.31) |
|||
| Total | 82 | 6,387 | 6,469 | |||||
*Indicates nonoverlapping 95% CIs (statistical significance).